



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

09 Nov 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally. **All final application documents MUST reach the RGMO seven (7) workdays before NIH application due date**

Important notices

- Request for Information (RFI): Updating the Alzheimer's Disease-Related Dementias Research Priorities ([NOT-NS-15-045](#))
- Notice Announcing the Creation of a Dedicated NINDS Biomarkers Repository for Biospecimen Banking for NINDS Biomarkers Projects ([NOT-NS-15-046](#))

1. Title: Applying Metabolomics to Drive Biomarker Discovery in Symptom Science

Letter of Intent due date: N/A Hyperlink: ([PA-16-029](#)) Type: R21
([PA-16-030](#)) RO1

Application Due Date: Standard dates apply and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement is to encourage applications on biomarker discovery that utilize metabolomics approaches to advance the understanding, assessment and management of symptoms.

Budget: R21: The combined budget for direct costs, excluding consortia F&A, for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

2. Title: Advancing Understanding, Prevention and Management of Infections Transmitted from Women to their Infants

Letter of Intent due date: N/A Hyperlink: ([PA-16-031](#)) Type: R21
([PA-16-032](#)) RO1

Application Due Date: Standard dates and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The purpose of this funding opportunity announcement (FOA) is to stimulate investigations including translational, epidemiologic and clinical studies and trials that improve the understanding, prevention and clinical outcomes of non-HIV infections transmitted from women to their offspring during pregnancy, labor and delivery, and breastfeeding. NICHD is committed to supporting research that will increase scientific understanding of and treatments for high-priority perinatal infections.

Budget: R21: The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year. **RO1:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period is 5 years.

3. Title: Stimulating Hematology Investigation: New Endeavors (SHINE)

Letter of Intent due date: N/A Hyperlink: ([PAS-16-033](#)) Type: R01

Application Due Date: Standard dates apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high quality hematology research relevant to the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In the SHINE program, NIDDK invites investigator-initiated research project grant applications in specific areas of basic and translational hematology research where needs and opportunities for progress are particularly timely. Specific research topic areas supported by the SHINE program, as outlined below, will change over time and be updated annually through the NIH Guide to Grants and Contracts.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

4. Title: Ancillary Studies to Major Ongoing Clinical Research Studies to Advance Areas of Scientific Interest within the Mission of the NIDDK

Letter of Intent due date: N/A

Hyperlink: [\(PAR-16-034\)](#)

Type: RO1

Application Due Date: [Standard dates](#) and [Standard AIDS dates](#) apply. Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free** (of both Grants.gov and eRA Commons errors) on the application due date.

Purpose: This Funding Opportunity Announcement (FOA) seeks to accelerate the pace and expand the breadth of scientific research on the clinical course, prevention and treatment of diseases within its mission by leveraging ongoing large, multi-center clinical research studies through ancillary studies. This Funding Opportunity Announcement (FOA) invites research project applications to conduct ancillary studies to major ongoing clinical research studies, including clinical trials and prospective observational studies. Applications submitted to this FOA must propose to collect new information and/or biological samples directly from participants of the ongoing parent study, and must address new research questions that are beyond those specified in the approved protocol of the parent study and are within the scientific mission of the NIDDK. This FOA cannot be used to extend the duration of the parent study.

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

5. Title: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics

Letter of Intent due date:

Hyperlink: [\(RFA-NS-16-013\)](#)

Type: R21/R33

Application Due Date: February 18, 2016; June 21, 2016; October 18, 2016; February 21, 2017; June 21, 2017; October 18, 2017. [Standard AIDS dates](#) (beginning on May 7, 2016). Apply by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. **Applicants should be aware that on-time submission means that an application is submitted error free to of both Grants.gov and eRA Commons.**

Purpose: This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Ideally, endpoints proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is not intended to support the development of animal and ex vivo model systems for the interrogation of disease etiology or for the identification of new drug targets. It is also not intended to support human clinical validation of model systems or pharmacodynamic markers. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

Budget: Direct costs are limited to \$250,000 per year, regardless of grant phase. The project period is limited to 3 Years, with no more than 2 years in the R21 phase and no more than 2 years in the R33 phase.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

DP3 – Institutional Training and Director Program Projects -Type 1 Diabetes Targeted Research Award: To support research tackling major challenges in type 1 diabetes and promoting new approaches to these challenges by scientific teams.

P20 – Research Program Projects and Centers -Exploratory Grant: To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

U24 – Resource-Related Research Projects – Cooperative Agreements: To support research projects contributing to improvement of the capability of resources to serve biomedical research.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

Complete [Glossary and acronym list of NIH Terms](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus. • Enquiries: **Dr Christa Coetsee** • Tel: 9838 • Email: cdevries@sun.ac.za